Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Drug Dose-Response Relationship. Found 65 abstracts

no pagination
Stromyer ML, Southerland MR, Satyal U, Sikder RK, Weader DJ, Baughman JA, Youngs WJ, Abbosh PH. Synthesis, characterization, and biological activity of a triphenylphosphonium-containing imidazolium salt against select bladder cancer cell lines. European journal of medicinal chemistry. 2020 Jan;185:111832.
Shaikh T, Wang LS, Egleston B, Burki M, Hoffman JP, Cohen SJ, Meyer JE. Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol. 2018 Jan;41(1):59-64.   PMCID: PMC4769977
Balar AV, Castellano D, O'Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Nov;18(11):1483-92.
de Oliveira JF, Lima TS, Vendramini-Costa DB, de Lacerda Pedrosa SC, Lafayette EA, da Silva RM, de Almeida SM, de Moura RO, Ruiz A, de Carvalho JE, de Lima M. Thiosemicarbazones and 4-thiazolidinones indole-based derivatives: Synthesis, evaluation of antiproliferative activity, cell death mechanisms and topoisomerase inhibition assay. European journal of medicinal chemistry. 2017 Aug 18;136:305-14.
Fan F, Yuan Z, Qin X, Li J, Zhang Y, Li Y, Yu T, Ji M, Ge J, Zheng M, Yang X, Bao H, Cheng X, Gu D, Zhao D, Wang J, Sun N, Chen Y, Wang H, Wang X, Parati G, Hou F, Xu X, Wang X, Zhao G, Huo Y. Optimal Systolic Blood Pressure Levels for Primary Prevention of Stroke in General Hypertensive Adults: Findings From the CSPPT (China Stroke Primary Prevention Trial). Hypertension (Dallas, Tex : 1979). 2017 Apr;69(4):697-704.
Kantarjian HM, Roboz GJ, Kropf PL, Yee KW, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Lancet Oncol. 2017 Oct;18(10):1317-26.   PMCID: PMC5925750
Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore BM, Nagorsen D, Hill JS, Stephenson J. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Oct;23(19):5703-10.
Seabloom DE, Galbraith AR, Haynes AM, Antonides JD, Wuertz BR, Miller WA, Miller KA, Steele VE, Miller MS, Clapper ML, O'Sullivan MG, Ondrey FG. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. Cancer prevention research (Philadelphia, Pa). 2017 Feb;10(2):116-23.   PMCID: PMC5690483
Solinski AE, Koval AB, Brzozowski RS, Morrison KR, Fraboni AJ, Carson CE, Eshraghi AR, Zhou G, Quivey RG, Voelz VA, Buttaro BA, Wuest WM. Diverted Total Synthesis of Carolacton-Inspired Analogs Yields Three Distinct Phenotypes in Streptococcus mutans Biofilms. J Am Chem Soc. 2017 May 31;139(21):7188-91.   PMCID: PMC5891724
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, Movva S, Davis LE, Okuno SH, Reed DR, Crowley J, Butterfield LH, Salazar R, Rodriguez-Canales J, Lazar AJ, Wistuba, Baker LH, Maki RG, Reinke D, Patel S. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-501.
Boushra M, Tous S, Fetih G, Korzekwa K, Lebo DB, Xue HY, Wong HL. Development and evaluation of viscosity-enhanced nanocarrier (VEN) for oral insulin delivery. International journal of pharmaceutics. 2016 Sep 10;511(1):462-72.
Boushra M, Tous S, Fetih G, Xue HY, Tran NT, Wong HL. Methocel-Lipid Hybrid Nanocarrier for Efficient Oral Insulin Delivery. Journal of pharmaceutical sciences. 2016 May;105(5):1733-40.
Goff LW, Cohen RB, Berlin JD, de Braud FG, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Stampino CG, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 May;22(9):2146-54.
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-79.   PMCID: PMC5569693
Skala E, Sitarek P, Toma M, Szemraj J, Radek M, Nieborowska-Skorska M, Skorski T, Wysokinska H, Sliwinski T. Inhibition of human glioma cell proliferation by altered Bax/Bcl-2-p53 expression and apoptosis induction by Rhaponticum carthamoides extracts from transformed and normal roots. The Journal of pharmacy and pharmacology. 2016 Nov;68(11):1454-64.
Higuchi T, Flies DB, Marjon NA, Mantia-Smaldone G, Ronner L, Gimotty PA, Adams S. CTLA-4 blockade synergizes therapeutically with PARP-inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol Res. 2015 Jul 02;3(11):1257-68.   PMCID: 4984269
Hochster HS, Uboha N, Messersmith W, Gold PJ, O Neil BH, Cohen D, Denlinger C, Cohen S, Leichman CG, Leichman L, Lenz HJ. Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemother Pharmacol. 2015 Jan;75(1):17-23.
Lecht S, Chiaverelli RA, Gerstenhaber J, Calvete JJ, Lazarovici P, Casewell NR, Harrison R, Lelkes PI, Marcinkiewicz C. Anti-angiogenic activities of snake venom CRISP isolated from Echis carinatus sochureki. Biochimica et biophysica acta. 2015 Jun;1850(6):1169-79.
Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol. 2015 May;33(13):1430-7.   PMCID: PMC4806782
Neelakantan H, Ward SJ, Walker EA. Discriminative stimulus effects of morphine and oxycodone in the absence and presence of acetic acid in male and female C57Bl/6 mice. Exp Clin Psychopharmacol. 2015 Aug;23(4):217-27.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Drug Dose-Response Relationship

Drug Dose-Response Relationship Female drug therapy pathology Male Middle Aged Aged administration & dosage therapeutic use drug effects metabolism adverse effects Treatment Outcome methods pharmacology chemistry Disease-Free Survival Adult genetics Drug Administration Schedule 80 and over Aged Antineoplastic Agents Monoclonal Antibodies mortality Survival Analysis immunology Prognosis Cell Proliferation physiology Neoplasm Invasiveness Maximum Tolerated Dose Kaplan-Meier Estimate Neoplasm Staging antagonists & inhibitors Cohort Studies Patient Safety Tumor Cell Line analogs & derivatives Intravenous Infusions Structure-Activity Relationship Oral Administration Cell Survival chemical synthesis Antineoplastic Combined Chemotherapy Protocols Molecular Structure Mice isolation & purification Drug Carriers United States Signal Transduction Preclinical Drug Evaluation Insulin Survival Rate statistics & numerical data Caco-2 Cells Deoxycytidine Risk Assessment prevention & control Glioma toxicity therapy Monoclonal Antibodies-Humanized Neoplasms Cisplatin Incidence Drug Delivery Systems etiology Antitumor Drug Screening Assays Prospective Studies Time Factors Inbred C57BL Mice Nanoparticles Lung Neoplasms physiopathology Apoptosis biosynthesis derivatives Sex Characteristics Benzimidazoles Ovarian Neoplasms Cancer Care Facilities Drug-Related Side Effects and Adverse Reactions Bone Neoplasms Type II Activin Receptors Macrolides Triphenylphosphonium salt Proto-Oncogene Proteins Urologic Neoplasms Macrophage Colony-Stimulating Factor antagonists & Metformin Early Termination of Clinical Trials Hypoglycemic Agents bcl-2-Associated X Protein Folic Acid Acute Pain Mutation Viscosity Oral delivery Radiation Injuries Viper Venoms Angiogenesis Inhibitors China Acetic Acid Chemoradiotherapy Age Factors epidemiology glioma primary cells Western Blotting Rhaponticum carthamoides Vitamin B Complex Soft Tissue Neoplasms Camptothecin Thiazolidinediones Rats Disease Progression blood Interleukin-1 Cell Movement Medicinal Plants Organophosphorus Compounds Remission Induction Anticancer therapy Transitional Cell Carcinoma Molecular Models Cell Cycle Checkpoints microbiology Migration Thiosemicarbazones Bax Agrobacterium Proto-Oncogene Proteins p21(ras) Mitochondrial Membrane Potential stability CTLA-4 Antigen Non-Small-Cell Lung Carcinoma Intravenous Administration Type II DNA Topoisomerases Encapsulation efficiency Experimental Neoplasms use Finland purification Angiogenesis Canada Proportional Hazards Models Pancreatic Neoplasms B7-H1 Antigen Ubiquitin-Protein Ligases T-Lymphocyte Subsets
Last updated on Sunday, July 05, 2020